Lumakras is the first marketed drug that’s capable of targeting KRAS mutations, which are commonly found in certain lung, colon and pancreatic cancers. Currently, Lumakras is only approved to treat locally advanced or metastatic non-small cell lung cancers, for which Amgen’s clinical trial evidence is most supportive of the drug’s benefit.
Data in colorectal cancer have been less compelling and the biotech company now is exploring combinations of Lumakras with other drugs, like the older targeted therapy Vectibix.
